Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients
BACKGROUNDSome HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT. METHODSIn this double-blind trial, 245 HIV-infected patients with exces...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2004-03, Vol.35 (3), p.239-252 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 252 |
|---|---|
| container_issue | 3 |
| container_start_page | 239 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 35 |
| creator | Kotler, Donald P Muurahainen, Norma Grunfeld, Carl Wanke, Christine Thompson, Melanie Saag, Michael Bock, Daena Simons, Gregg Gertner, Joseph M |
| description | BACKGROUNDSome HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT.
METHODSIn this double-blind trial, 245 HIV-infected patients with excess VAT were randomized to receive placebo (PL), recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD) or 4 mg on alternate days (AD) for 12 weeks. For weeks 12 to 24, DD patients were rerandomized to PL (DD-PL) or AD (DD-AD), AD patients continued on AD (AD-AD), and PL patients were switched to DD (PL-DD).
RESULTSFrom baseline to week 12, VAT decreased significantly compared with PL in DD (−8.6%, P < 0.001) but not in AD (−4.2%, P = 0.052). Trunk-to-limb fat ratio decreased significantly in both (P < 0.001) compared with PL, as did total cholesterol and non–high-density lipoprotein (HDL) cholesterol (−4.5% and −7.5% in DD, −4.3% and −6.2% in AD). At week 24, all groups displayed significant (P < 0.05) reductions in VAT (−5.3% to −9.5%) and trunk fat (−7.8% to −22.8%). DD-AD and AD-AD also displayed significant (P < 0.05) reductions in non-HDL cholesterol.
CONCLUSIONSThese results suggest that r-hGH dosed at 4 mg daily for 12 weeks decreases VAT and cholesterol concentrations in HIV-infected patients with excess VAT. The optimal regimen to sustain these effects awaits determination. |
| doi_str_mv | 10.1097/00126334-200403010-00004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71823056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71823056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5604-23ed5eb679824b48fa9ce5b23644e40721584145c3097a3c332adcb38940fd233</originalsourceid><addsrcrecordid>eNqFkl9rFDEUxYNYbLv6FSQI-jaavzOZx6Wt3YWCfah9DZnMHTY1k6zJDEu_vVl3q1KQ5iU38Dv3cu4JQpiSz5S0zRdCKKs5FxUjRBBOKKlIOeIVOqOtEFWjlHhdaslkJSiXp-g854eiqoVo36BTKklTM67O0HQ1DGCnjOOAr1PcTRu8immMAXAMeNmF8jAe37tsIZVi2bttzIDvXM4z4KW18zh7M7lCm9Djy8fs3db1MDqDXcCr9X21DvsR0OPbwkGY8lt0Mhif4d3xXqDvX6_uLlbVzbfr9cXyprKyJsUch15CVzetYqITajCtBdkxXlyAIA2jUgkqpOVlJ4ZbzpnpbcdVK8jQM84X6NOh7zbFnzPkSY97H96bAHHOuqGKcSLrF0HatFwJ0RTwwzPwIc4pFBO6zKu5YCWOBVIHyKaYc4JBb5MbTXrUlOh9fvopP_0nP_07vyJ9f-w_dyP0f4XHwArw8QiYbI0fkgnW5X84qcpiWOHEgdtFP0HKP_y8g6Q3YPy00f_7P_wXLaSwZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233634240</pqid></control><display><type>article</type><title>Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients</title><source>Ovid Lippincott Williams and Wilkins Journal Legacy Archive</source><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Free E- Journals</source><creator>Kotler, Donald P ; Muurahainen, Norma ; Grunfeld, Carl ; Wanke, Christine ; Thompson, Melanie ; Saag, Michael ; Bock, Daena ; Simons, Gregg ; Gertner, Joseph M</creator><creatorcontrib>Kotler, Donald P ; Muurahainen, Norma ; Grunfeld, Carl ; Wanke, Christine ; Thompson, Melanie ; Saag, Michael ; Bock, Daena ; Simons, Gregg ; Gertner, Joseph M ; Serostim in Adipose Redistribution Syndrome Study Group</creatorcontrib><description>BACKGROUNDSome HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT.
METHODSIn this double-blind trial, 245 HIV-infected patients with excess VAT were randomized to receive placebo (PL), recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD) or 4 mg on alternate days (AD) for 12 weeks. For weeks 12 to 24, DD patients were rerandomized to PL (DD-PL) or AD (DD-AD), AD patients continued on AD (AD-AD), and PL patients were switched to DD (PL-DD).
RESULTSFrom baseline to week 12, VAT decreased significantly compared with PL in DD (−8.6%, P < 0.001) but not in AD (−4.2%, P = 0.052). Trunk-to-limb fat ratio decreased significantly in both (P < 0.001) compared with PL, as did total cholesterol and non–high-density lipoprotein (HDL) cholesterol (−4.5% and −7.5% in DD, −4.3% and −6.2% in AD). At week 24, all groups displayed significant (P < 0.05) reductions in VAT (−5.3% to −9.5%) and trunk fat (−7.8% to −22.8%). DD-AD and AD-AD also displayed significant (P < 0.05) reductions in non-HDL cholesterol.
CONCLUSIONSThese results suggest that r-hGH dosed at 4 mg daily for 12 weeks decreases VAT and cholesterol concentrations in HIV-infected patients with excess VAT. The optimal regimen to sustain these effects awaits determination.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/00126334-200403010-00004</identifier><identifier>PMID: 15076238</identifier><identifier>CODEN: JDSRET</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adipose Tissue - anatomy & histology ; Adipose Tissue - drug effects ; Adolescent ; Adult ; AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Biological and medical sciences ; Body fat ; Cholesterol - blood ; Continental Population Groups ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Female ; Fundamental and applied biological sciences. Psychology ; HIV ; HIV Infections - blood ; HIV Infections - drug therapy ; HIV Infections - physiopathology ; Hormones ; Human Growth Hormone - administration & dosage ; Human Growth Hormone - therapeutic use ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Hyperlipidemias - drug therapy ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Placebos ; Reproducibility of Results ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology ; Viscera</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2004-03, Vol.35 (3), p.239-252</ispartof><rights>2004 Lippincott Williams & Wilkins, Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Mar 1, 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5604-23ed5eb679824b48fa9ce5b23644e40721584145c3097a3c332adcb38940fd233</citedby><cites>FETCH-LOGICAL-c5604-23ed5eb679824b48fa9ce5b23644e40721584145c3097a3c332adcb38940fd233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf><![CDATA[$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&PDF=y&D=ovft&AN=00126334-200403010-00004$$EPDF$$P50$$Gwolterskluwer$$H]]></linktopdf><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00126334-200403010-00004$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,780,784,4609,27924,27925,64666,65461</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15580722$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15076238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotler, Donald P</creatorcontrib><creatorcontrib>Muurahainen, Norma</creatorcontrib><creatorcontrib>Grunfeld, Carl</creatorcontrib><creatorcontrib>Wanke, Christine</creatorcontrib><creatorcontrib>Thompson, Melanie</creatorcontrib><creatorcontrib>Saag, Michael</creatorcontrib><creatorcontrib>Bock, Daena</creatorcontrib><creatorcontrib>Simons, Gregg</creatorcontrib><creatorcontrib>Gertner, Joseph M</creatorcontrib><creatorcontrib>Serostim in Adipose Redistribution Syndrome Study Group</creatorcontrib><title>Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>BACKGROUNDSome HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT.
METHODSIn this double-blind trial, 245 HIV-infected patients with excess VAT were randomized to receive placebo (PL), recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD) or 4 mg on alternate days (AD) for 12 weeks. For weeks 12 to 24, DD patients were rerandomized to PL (DD-PL) or AD (DD-AD), AD patients continued on AD (AD-AD), and PL patients were switched to DD (PL-DD).
RESULTSFrom baseline to week 12, VAT decreased significantly compared with PL in DD (−8.6%, P < 0.001) but not in AD (−4.2%, P = 0.052). Trunk-to-limb fat ratio decreased significantly in both (P < 0.001) compared with PL, as did total cholesterol and non–high-density lipoprotein (HDL) cholesterol (−4.5% and −7.5% in DD, −4.3% and −6.2% in AD). At week 24, all groups displayed significant (P < 0.05) reductions in VAT (−5.3% to −9.5%) and trunk fat (−7.8% to −22.8%). DD-AD and AD-AD also displayed significant (P < 0.05) reductions in non-HDL cholesterol.
CONCLUSIONSThese results suggest that r-hGH dosed at 4 mg daily for 12 weeks decreases VAT and cholesterol concentrations in HIV-infected patients with excess VAT. The optimal regimen to sustain these effects awaits determination.</description><subject>Adipose Tissue - anatomy & histology</subject><subject>Adipose Tissue - drug effects</subject><subject>Adolescent</subject><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Body fat</subject><subject>Cholesterol - blood</subject><subject>Continental Population Groups</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - physiopathology</subject><subject>Hormones</subject><subject>Human Growth Hormone - administration & dosage</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Placebos</subject><subject>Reproducibility of Results</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virology</subject><subject>Viscera</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl9rFDEUxYNYbLv6FSQI-jaavzOZx6Wt3YWCfah9DZnMHTY1k6zJDEu_vVl3q1KQ5iU38Dv3cu4JQpiSz5S0zRdCKKs5FxUjRBBOKKlIOeIVOqOtEFWjlHhdaslkJSiXp-g854eiqoVo36BTKklTM67O0HQ1DGCnjOOAr1PcTRu8immMAXAMeNmF8jAe37tsIZVi2bttzIDvXM4z4KW18zh7M7lCm9Djy8fs3db1MDqDXcCr9X21DvsR0OPbwkGY8lt0Mhif4d3xXqDvX6_uLlbVzbfr9cXyprKyJsUch15CVzetYqITajCtBdkxXlyAIA2jUgkqpOVlJ4ZbzpnpbcdVK8jQM84X6NOh7zbFnzPkSY97H96bAHHOuqGKcSLrF0HatFwJ0RTwwzPwIc4pFBO6zKu5YCWOBVIHyKaYc4JBb5MbTXrUlOh9fvopP_0nP_07vyJ9f-w_dyP0f4XHwArw8QiYbI0fkgnW5X84qcpiWOHEgdtFP0HKP_y8g6Q3YPy00f_7P_wXLaSwZg</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Kotler, Donald P</creator><creator>Muurahainen, Norma</creator><creator>Grunfeld, Carl</creator><creator>Wanke, Christine</creator><creator>Thompson, Melanie</creator><creator>Saag, Michael</creator><creator>Bock, Daena</creator><creator>Simons, Gregg</creator><creator>Gertner, Joseph M</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20040301</creationdate><title>Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients</title><author>Kotler, Donald P ; Muurahainen, Norma ; Grunfeld, Carl ; Wanke, Christine ; Thompson, Melanie ; Saag, Michael ; Bock, Daena ; Simons, Gregg ; Gertner, Joseph M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5604-23ed5eb679824b48fa9ce5b23644e40721584145c3097a3c332adcb38940fd233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adipose Tissue - anatomy & histology</topic><topic>Adipose Tissue - drug effects</topic><topic>Adolescent</topic><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Body fat</topic><topic>Cholesterol - blood</topic><topic>Continental Population Groups</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - physiopathology</topic><topic>Hormones</topic><topic>Human Growth Hormone - administration & dosage</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Placebos</topic><topic>Reproducibility of Results</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virology</topic><topic>Viscera</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotler, Donald P</creatorcontrib><creatorcontrib>Muurahainen, Norma</creatorcontrib><creatorcontrib>Grunfeld, Carl</creatorcontrib><creatorcontrib>Wanke, Christine</creatorcontrib><creatorcontrib>Thompson, Melanie</creatorcontrib><creatorcontrib>Saag, Michael</creatorcontrib><creatorcontrib>Bock, Daena</creatorcontrib><creatorcontrib>Simons, Gregg</creatorcontrib><creatorcontrib>Gertner, Joseph M</creatorcontrib><creatorcontrib>Serostim in Adipose Redistribution Syndrome Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotler, Donald P</au><au>Muurahainen, Norma</au><au>Grunfeld, Carl</au><au>Wanke, Christine</au><au>Thompson, Melanie</au><au>Saag, Michael</au><au>Bock, Daena</au><au>Simons, Gregg</au><au>Gertner, Joseph M</au><aucorp>Serostim in Adipose Redistribution Syndrome Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>35</volume><issue>3</issue><spage>239</spage><epage>252</epage><pages>239-252</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><coden>JDSRET</coden><abstract>BACKGROUNDSome HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT.
METHODSIn this double-blind trial, 245 HIV-infected patients with excess VAT were randomized to receive placebo (PL), recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD) or 4 mg on alternate days (AD) for 12 weeks. For weeks 12 to 24, DD patients were rerandomized to PL (DD-PL) or AD (DD-AD), AD patients continued on AD (AD-AD), and PL patients were switched to DD (PL-DD).
RESULTSFrom baseline to week 12, VAT decreased significantly compared with PL in DD (−8.6%, P < 0.001) but not in AD (−4.2%, P = 0.052). Trunk-to-limb fat ratio decreased significantly in both (P < 0.001) compared with PL, as did total cholesterol and non–high-density lipoprotein (HDL) cholesterol (−4.5% and −7.5% in DD, −4.3% and −6.2% in AD). At week 24, all groups displayed significant (P < 0.05) reductions in VAT (−5.3% to −9.5%) and trunk fat (−7.8% to −22.8%). DD-AD and AD-AD also displayed significant (P < 0.05) reductions in non-HDL cholesterol.
CONCLUSIONSThese results suggest that r-hGH dosed at 4 mg daily for 12 weeks decreases VAT and cholesterol concentrations in HIV-infected patients with excess VAT. The optimal regimen to sustain these effects awaits determination.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>15076238</pmid><doi>10.1097/00126334-200403010-00004</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2004-03, Vol.35 (3), p.239-252 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71823056 |
| source | Ovid Lippincott Williams and Wilkins Journal Legacy Archive; MEDLINE; Journals@Ovid Complete; Free E- Journals |
| subjects | Adipose Tissue - anatomy & histology Adipose Tissue - drug effects Adolescent Adult AIDS/HIV Anti-HIV Agents - therapeutic use Biological and medical sciences Body fat Cholesterol - blood Continental Population Groups Double-Blind Method Drug Administration Schedule Drug therapy Female Fundamental and applied biological sciences. Psychology HIV HIV Infections - blood HIV Infections - drug therapy HIV Infections - physiopathology Hormones Human Growth Hormone - administration & dosage Human Growth Hormone - therapeutic use Human immunodeficiency virus Human viral diseases Humans Hyperlipidemias - drug therapy Infectious diseases Male Medical sciences Microbiology Middle Aged Miscellaneous Placebos Reproducibility of Results Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology Viscera |
| title | Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A53%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Growth%20Hormone%20on%20Abnormal%20Visceral%20Adipose%20Tissue%20Accumulation%20and%20Dyslipidemia%20in%20HIV-Infected%20Patients&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Kotler,%20Donald%20P&rft.aucorp=Serostim%20in%20Adipose%20Redistribution%20Syndrome%20Study%20Group&rft.date=2004-03-01&rft.volume=35&rft.issue=3&rft.spage=239&rft.epage=252&rft.pages=239-252&rft.issn=1525-4135&rft.eissn=1944-7884&rft.coden=JDSRET&rft_id=info:doi/10.1097/00126334-200403010-00004&rft_dat=%3Cproquest_cross%3E71823056%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233634240&rft_id=info:pmid/15076238&rfr_iscdi=true |